First-line treatment of advanced nonsmall cell lung carcinoma with docetaxel and vinorelbine

✍ Scribed by Charalambos Kourousis; Nicos Androulakis; Stelios Kakolyris; John Souglakos; George Maltezakis; George Metaxaris; George Chalkiadakis; George Samonis; John Vlachonikolis; Vassilis Georgoulias

• Publisher: John Wiley and Sons
• Year: 1998
• Tongue: English
• Weight: 87 KB
• Volume: 83
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/(sici)1097-0142(19981115)83:10<2083::aid-cncr6>3.0.co;2-i

✦ Synopsis

BACKGROUND. Docetaxel and vinorelbine are active agents in the treatment of nonsmall cell lung carcinoma (NSCLC). The efficacy and toxicity of this combination was evaluated in a Phase II study in patients with advanced NSCLC.

METHODS.

Forty-six chemotherapy-naive patients (44 men and 2 women with a median age of 64 years) with NSCLC (11 with Stage IIIB and 35 with Stage IV disease) were entered into the study; the World Health Organization (WHO) performance status was 0, 1, and 2 in 32, 11, and 3 patients, respectively. Patients received vinorelbine (25 mg/m 2 ) on Day 1 and docetaxel (100 mg/m 2 ) on Day 2 in cycles repeated every 3 weeks. Granulocyte-colony stimulating factor was given to all patients from Day 3 to Day 10.